Clinical Trial Update: MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ruxolitinib to hydroxycarbamide or interferon as first-line therapy for high-risk polycythemia vera, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Hydroxycarbamide (hydroxycarbamide)
• Interferon (interferon)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Birmingham | Conditions: Polycythemia Vera | Phase 3 | Status: RECRUITING